In this edition, guselkumab brings 'stringent' control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here: Guselkumab brings active psoriatic arthritis into 'stringent' control through 2 years Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription FDA approves biosimilar Pyzchiva for all approved Stelara indications Tofacitinib effective for juvenile idiopathic arthritis through 4 years Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes References: Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094. Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277. Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378. Press Release Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.

Ver todos los episodios